5 drug(s) with this reaction
57,882 total reports
Psoriasis has been reported as an adverse reaction across 5 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 57,882 adverse event reports mention psoriasis in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with psoriasis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have psoriasis listed in their FDA adverse event reports, sorted by report count:
In addition to psoriasis, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
5 drug(s) manufactured by Abbvie Inc have psoriasis listed in their FDA adverse event reports: Humira, ADALIMUMAB, RISANKIZUMAB-RZAA, UPADACITINIB, FENOFIBRATE.
There are a combined 57,882 reports of psoriasis across 5 Abbvie Inc drug(s) in the FDA adverse event database.